Abstract
Non-melanoma skin cancers (NMSCs) are the most common malignancies after solid organ transplantation. Their incidence increases with time after transplantation. Calcineurin-inhibitors (CNIs) and azathioprine are known as skin neoplasia-initiating and -enhancing immunosuppressants. In contrast, increasing clinical experience suggests a relevant antiproliferative effect of mammalian target of rapamycin inhibitors, also named proliferation signal inhibitors (PSIs). We report the case of a cardiac allograft recipient with an impressive and consolidated reduction of recurrent NMSC, observed after conversion from CNI-therapy to a PSI-based protocol.
Copyright © 2010 Elsevier Inc. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Calcineurin Inhibitors*
-
Carcinoma, Squamous Cell / enzymology
-
Carcinoma, Squamous Cell / etiology*
-
Carcinoma, Squamous Cell / pathology
-
Carcinoma, Squamous Cell / therapy
-
Cell Proliferation / drug effects*
-
Drug Therapy, Combination
-
Everolimus
-
Heart Transplantation / adverse effects*
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Photochemotherapy
-
Signal Transduction / drug effects*
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
-
Skin Neoplasms / enzymology
-
Skin Neoplasms / etiology*
-
Skin Neoplasms / pathology
-
Skin Neoplasms / therapy
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
Tacrolimus / adverse effects*
-
Time Factors
-
Transplantation, Homologous
-
Treatment Outcome
Substances
-
Calcineurin Inhibitors
-
Immunosuppressive Agents
-
Everolimus
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sirolimus
-
Tacrolimus